FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer

BACKGROUND: The aim of this study was to investigate the efficacy and safety of first-line panitumumab plus folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in patients with wild-type KRAS and wild-type NRAS metastatic colorectal cancer (mCRC). METHODS: Patients with wild-type KRAS and wild-typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Geredeli, Caglayan, Yasar, Nurgul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870197/
https://www.ncbi.nlm.nih.gov/pubmed/29587749
http://dx.doi.org/10.1186/s12957-018-1359-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870197/
https://www.ncbi.nlm.nih.gov/pubmed/29587749
http://dx.doi.org/10.1186/s12957-018-1359-9

Ejemplares similares